Methylphenidate transdermal system in adults with past stimulant misuse: an open-label trial

J Atten Disord. 2011 Oct;15(7):539-44. doi: 10.1177/1087054710371171. Epub 2010 Jun 10.


Objective: This 8-week, open-label trial assessed the efficacy of methylphenidate transdermal system (MTS) in 14 adult individuals diagnosed with ADHD and with a history of stimulant misuse, abuse, or dependence.

Method: The primary efficacy endpoint was the Wender-Reimherr Adult ADHD Scale (WRAADS), and secondary efficacy endpoints included the Clinical Global Impression (CGI) ratings and substance abuse as quantified by urine drug screens and self-reported use.

Results: Significant improvements from baseline were found on both the WRAADS and CGI measurements. No abuse of the study medication was observed.

Conclusion: The findings suggested that MTS may improve ADHD symptoms in adults with a history of stimulant misuse; however, there were limitations. The study data showed the need for subsequent randomized studies that further explore findings made in this study.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Aged
  • Amphetamine-Related Disorders / complications
  • Amphetamine-Related Disorders / diagnosis*
  • Attention Deficit Disorder with Hyperactivity / complications
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Central Nervous System Stimulants / administration & dosage
  • Central Nervous System Stimulants / therapeutic use*
  • Female
  • Humans
  • Male
  • Methylphenidate / administration & dosage
  • Methylphenidate / therapeutic use*
  • Middle Aged
  • Treatment Outcome


  • Central Nervous System Stimulants
  • Methylphenidate